Gilead Sciences (WBO:GILD) Days Sales Outstanding : 61.26 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Days Sales Outstanding?

Gilead Sciences's average Accounts Receivable for the three months ended in Mar. 2025 was €4,140 Mil. Gilead Sciences's Revenue for the three months ended in Mar. 2025 was €6,167 Mil. Hence, Gilead Sciences's Days Sales Outstanding for the three months ended in Mar. 2025 was 61.26.

The historical rank and industry rank for Gilead Sciences's Days Sales Outstanding or its related term are showing as below:

WBO:GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.17 Med: 60.61 Max: 63.51
Current: 57.74

During the past 13 years, Gilead Sciences's highest Days Sales Outstanding was 63.51. The lowest was 56.17. And the median was 60.61.

WBO:GILD's Days Sales Outstanding is ranked better than
65.03% of 958 companies
in the Drug Manufacturers industry
Industry Median: 72.17 vs WBO:GILD: 57.74

Gilead Sciences's Days Sales Outstanding declined from Mar. 2024 (63.56) to Mar. 2025 (61.26).

Gilead Sciences Days Sales Outstanding Historical Data

The historical data trend for Gilead Sciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Days Sales Outstanding Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

65.15

60.40

60.13

64.46

56.45

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Sales Outstanding	Get a 7-Day Free Trial															63.56	60.94	56.81	52.73	61.26

Competitive Comparison of Gilead Sciences's Days Sales Outstanding

For the Drug Manufacturers - General subindustry, Gilead Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Gilead Sciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Gilead Sciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (4273.22	+	4221.1)	/	2 )	/	27460.07	*	365
=	4247.16					/	27460.07	*	365
=	56.45

Gilead Sciences's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding (Q: Mar. 2025 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )	/	Revenue (A: Mar. 2025 )	*	Days in Period
=	( (4221.1	+	4058.9)	/	2 )	/	6166.975	*	365 / 4
=	4140					/	6166.975	*	365 / 4
=	61.26

Gilead Sciences (WBO:GILD) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Gilead Sciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (WBO:GILD) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).